Nipocalimab

Hemolytic anemias include PNH, aHUS, and wAIHA. Anti-C5 therapy is key for PNH and aHUS. New treatments target upstream complement cascade components. Novel therapies for wAIHA include fostamatinib and sovleplenib.

Cyrus Biotechnology's engineered IgG-degrading enzyme, CYR241, shows potent activity and no anti-drug antibodies (ADAs) in a rabbit redosing model, unlike wild type IdeS which elicits strong ADA responses. CYR241 maintains potency upon redosing and is optimized for glycosylation and low MHC binding.

The FcRn inhibitor market report by ResearchAndMarkets.com provides insights into historical and competitive landscapes, market trends, emerging drugs, and forecasts from 2020 to 2034. Key players like Johnson & Johnson, UCB Biopharma, Pfizer, and Immunovant are developing FcRn inhibitors for autoimmune diseases. Prominent drugs include VYVGART, RYSTIGGO, and batoclimab, with positive trial results and FDA approvals. The market is expected to grow due to increasing diagnoses and emerging therapies.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Health Canada approves Johnson & Johnson's CARVYKTI as the first B-cell maturation antigen-targeted therapy for multiple myeloma patients, based on Phase III CARTITUDE-4 trial results showing a 74% reduction in disease progression or death risk compared to standard care.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

The FDA granted breakthrough therapy designation to nipocalimab (Johnson & Johnson) for treating moderate-to-severe Sjögren disease (SjD), the first for this condition. SjD, a chronic autoantibody disease, primarily causes dry eyes and mouth, often coexisting with rheumatoid arthritis and lupus. Nipocalimab, an FcRn blocker, showed positive results in a phase 2 study, with improvements in disease activity and symptoms like dryness. A phase 3 study is ongoing, aiming to address the disease's underlying causes and improve patient outcomes.